News

ImStem Affiliate in China Receives Clinical Trial Authorization for IMS001 in Multiple Sclerosis

Zhuhai Hengqin ImStem Biotechnology Co., Ltd. received NMPA CDE clinical trial authorization for IMS001 Injection in worsening relapsing-remitting MS and active secondary progressive MS.

Prof. Rudolf Jaenisch joins ImStem Biotechnology as Member of its Scientific Advisory Board

Rudolf Jaenisch, a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research, joins ImStem Biotechnology as Member of Scientific Advisory Board.

Watch ImStem’s scientists introduce its innovative stem cell technology on Bloomberg

Bloomberg to Air ImStem’s First-ever Stem Cell Technology on June 4th

First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS

The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.

ImStem Announces First US Multiple Sclerosis Patient Has Been Dosed with its IMS001

ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.

TIP Company ImStem Biotechnology Doses First MS Patient in Clinical Trial

UConn TIP company ImSTEM Biotechnology is conducting a clinical trial to test their experimental human embryonic stem cell-derived mesenchymal stem cell therapy for the treatment of multiple sclerosis.

AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS. ImStem’s investigational MSC candidate IMS001 is to be considered for further development in COVID19 and ARDS from other causes.

ImStem Biotechnology to Launch Phase 1 Trial Testing IMS001 for MS

The FDA has lifted the clinical hold and cleared the investigational new drug (IND) application to assess IMS001 in the treatment of multiple sclerosis (MS).

ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

The FDA has lifted the clinical hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS).

T-MSC granted the patent authorization of Japan and Australia

The core technology of ImStem Biotechnology Inc. has recently been granted the patent authorization of the national patent office of Japan and Australia.

ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases

The U.S. Patent and Trademark Office has issued a patent for human embryonic stem cell derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production.

ImStem Biotechnology, Inc. Makes Progress on Multiple Sclerosis Treatment with Embryonic Stem Cells

ImStem Biotechnology, Inc.(ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.

Pluripotent stem cell expert Hongkui Deng Joins ImStem's Scientific Advisory Board

ImStem Biotechnology, (ImStem) announced today that Dr. Hongkui Deng, Ph.D. has been appointed to the Company's Scientific Advisory Board.

ImStem won $1.1 million stem cell research grant from State of Connecticut

ImStem Biotechnology’s Drs. Xiaofang Wang and Ren-He Xu were awarded $1.1 million in state stem cell funding.

The State's Connecticut Innovations Commits $150,000 to ImStem Biotechnology of Farmington

“ImStem's work is not only important from a public health standpoint, but is part of a wider growing biotech industry that is creating well-paying, high-tech jobs,” said Mike Demicco (D-Farmington).